drugset / Trial / NCT04095208
Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter study assessing the efficacy of nivolumab in association with relatlimab.
Timeline
- Start
- 2020-02-27
- Primary completion
- 2024-09-29
- Completion
- 2026-03-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Relatlimab | Monoclonal antibody | 80 mg | Intravenous |